NEFL and myeloid sarcoma: Serum neurofilament light chain (sNFL) has been intensively investigated as an MS biomarker; however, it is challenging to use it in a clinical setting, as there is a significant overlap between the baseline sNFL level of patients with MS and their controls, who may have migraine or conversion disorder [10,11].